Publication Type:

Journal Article

Source:

Funct Integr Genomics, Volume 17, Issue 4, p.375-385 (2017)

URL:

https://www.ncbi.nlm.nih.gov/pubmed/28470340

Keywords:

Antineoplastic Agents, BRCA1 protein, Breast Neoplasms, Chlorambucil, drug design, female, Genetic Predisposition to Disease, Humans, Pharmacogenetics, Polymorphism, Single Nucleotide, Precision Medicine

Abstract:

<p>The proneness of diseases and susceptibility towards drugs vary from person to person. At present, there is a strong demand for the personalization of drugs. The genetic signature behind proneness of the disease has been studied through a comprehensive 'octopodial approach'. All the genetic variants included in the approach have been introduced. The breast cancer associated with BRCA1 mutation has been taken as the illustrative example to introduce all these factors. The genetic variants associated with the drug action of tamoxifen have been fully illustrated in the manuscript. The design of a new personalized anti-breast cancer drug has been explained in the third phase. For the design of new personalized drugs, a metabolite of anti-cancer drug chlorambucil has been taken as the template. The design of drug has been made with respect to the protein 1T15 of BRCA1 gene corresponding to the genetic signature of rs28897696.</p>

Cite this Research Publication

P. M. Iyer, Karthikeyan, S., P Kumar, S., and Namboori, P. K. Krishnan, “Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach.”, Funct Integr Genomics, vol. 17, no. 4, pp. 375-385, 2017.